Parnell Pharmaceuticals Holdings Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2016. For the six months, the company reported revenue of AUD 4,927,965 compared to AUD 4,927,965 a year ago. The company reported loss before income tax of AUD 12,467,007 compared to AUD 2,983,338 and loss of AUD 12,477,931 or AUD 0.85 per basic and diluted share compared to AUD 2,985,444 or AUD 0.22 per basic and diluted share for the last year.

The company expected full-year 2016 revenue growth to be of similar magnitude. The company expected continued growth for the full year of 2016 from the existing contract and anticipate potentially adding further contracts in the second-half of 2016.